These findings identify a miR-1202-NAIF1-MAPK/ERK regulatory axis that contributes to NPC radioresistance and highlight miR-1202 as a potential biomarker and therapeutic target to improve radiotherapy outcomes. The gene discussed is NAIF1; the disease is nasopharyngeal carcinoma.